scFv(TACSTD2)-CD28-OX40-CD3zeta CAR-T Lentivirus

The scFv(TACSTD2)-CD28-OX40-CD3zeta CAR-T Lentivirus is a specialized genetic engineering tool designed to reprogram human T lymphocytes to target Tumor-Associated Calcium Signal Transducer 2 (TACSTD2), also known as TROP2. This lentiviral vector facilitates the expression of a third-generation chimeric antigen receptor (CAR) on the T cell surface. The construct consists of a high-affinity single-chain variable fragment (scFv) derived from an anti-TROP2 monoclonal antibody, which is linked to a complex intracellular signaling domain. This signaling architecture integrates the primary activation signal from CD3zeta with two potent costimulatory domains, CD28 and OX40. By combining these elements, the CAR is engineered to maximize T cell proliferation, enhance cytokine production, and promote long-term survival. The lentiviral delivery system ensures stable integration of the CAR transgene into the host cell genome, allowing for the generation of a consistent and functional population of therapeutic effector cells.

This lentiviral product is primarily utilized in the development and preclinical evaluation of adoptive cell therapies targeting a wide range of epithelial malignancies. Since TROP2 is highly expressed in various solid tumors, including breast, lung, colonic, and pancreatic carcinomas, this CAR-T construct serves as a pivotal model for studying anti-tumor efficacy in these indications. Researchers employ this lentivirus to perform in vitro cytotoxicity assays, assess cytokine release profiles, and evaluate the metabolic fitness of engineered T cells. Furthermore, the inclusion of the OX40 domain makes it an excellent tool for investigating T cell persistence and the prevention of exhaustion within the challenging immunosuppressive tumor microenvironment. It is also used in the optimization of viral transduction protocols and as a benchmark for comparing the performance of third-generation CAR designs against traditional second-generation constructs in pilot studies and translational oncology research.